Accumulated Balances Related To Each Component Of Other Comprehensive Income Loss [Text Block]
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The period, in months, over which the effective portion of changes in fair value of cash flow hedges that is temporarily reported in accumulated other comprehensive income or loss is expected to be reclassified to earnings.
No authoritative reference available.
The closing stock price, as of the balance sheet date, used in the calculation of total pre-tax intrinsic value of stock options.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Write-off of the carrying amount of intangible assets associated with all or a portion of a subsidiary that is sold in the period.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Schedule of Weighted Average Assumptions of Stock Options[Text Block]
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The amount of the restructuring liability transferred as a result of a divestiture
No authoritative reference available.
The amount of issuance costs deducted from total proceeds on the subsidiary sale of stock transaction.
No authoritative reference available.
Payment received for the acquisition of an interest in a product license. Deferred income recognized from this payment is amortized to other income over the expected expiration of the license.
No authoritative reference available.
Schedule Of Restricted Stock Awards And Restricted Stock Units And Market Share Units [Text Block]
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The number of years in the supply agreement.
No authoritative reference available.
This element represents the payment made to extinguish outstanding debt.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The aggregate sum of the gross carrying value of intangible assets, excluding goodwill, less accumulated amortization and any impairment charges.
No authoritative reference available.
Collaboration Percentage Of Loss Recognized
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Schedule Of Fair Value Of Pension And Postretirement Plan Assets By Asset Category [Text Block]
No authoritative reference available.
This element represents unusual or infrequent items during the period related to upfront licensing and milestone payments.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The amount of expense recognized in the current period in discontinued operations that reflects the allocation of the cost of tangible assets over the assets' useful lives.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The accumulated amount of amortization of total intangible assets, excluding goodwill.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Carrying value as of the balance sheet date of obligations incurred related to litigation that are expected to be paid within one year.
No authoritative reference available.
The amount of acquisition cost of a business combination allocated to deferred income tax assets/liabilities.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The number of trading days immediately preceding the grant or vest date.
No authoritative reference available.
Schedule Of Changes To Allowances.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The percentage of certain collaboration product commercialization expenses that will be reimbursed by the collaboration partner pursuant to the collaboration agreement.
No authoritative reference available.
This element represents the adjustment to principal value of long term debt related to the fair value of interest rate swaps.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Summary of reductions to trade receivables and listing of accrued rebates and returns liabilities.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The tax effect as of the balance sheet date of the amount of estimated future tax deductions arising from other foreign temporary differences.
No authoritative reference available.
The percentage ownership interest in a collaboration partner.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
This element represents the amount of recognized share-based compensation during the period as expense in the income statement and the change in additional paid in capital attributable to shares issued from treasury stock for share exercises.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The number of plaintiffs whose claims are to be resolved as a result of entering into two separate settlements in principle.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Description and amounts of deferred income at the end of the reporting period, and description and amounts of significant changes that occurred during the reporting period. Deferred income is a liability as of the balance sheet date related to a revenue or income producing activity for which revenue or income has not yet been recognized.
No authoritative reference available.
The number of regional organizations which distribute and sell the entity's products.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Charges incurred during the period attributable to restructuring and the productivity transformation initiative, net of any related productivity transformation initiative gains recognized during the period.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The percentage share of pre-tax profit/loss received from the net sales of a collaboration partner to be shared further equally with another collaboration partner.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The term in years over which restrictions on common stock grants expire from grant date anniversary.
No authoritative reference available.
Increase representing the amount charged against earnings in discontinued operations in the period for a specified incurred and estimated type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Schedule Of Activity Of Financial Assets Utilizing Level 3 Fair Value Measurement [Text Block]
No authoritative reference available.
The aggregate amount of deferred income as of balance sheet date. Deferred income is a liability related to a revenue or other income producing activity for which revenue or other income has not yet been recognized, and is expected to be recognized in the next twelve months. Deferred income is recorded when consideration from a customer is received before achieving certain criteria that must be met for revenue or other income to be recognized in conformity with GAAP.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The period, in years, over which shared based compensation equity awards, other than options, vest.
No authoritative reference available.
Carrying value as of the balance sheet date of obligations and payables pertaining to research and development.
No authoritative reference available.
The expense attributable to the termination of contingent obligations related to certain milestone payments. This payment is recognized in operating expenses in research and development.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The minimum amount of certain operational expenses for the collaboration reimbursement percentage.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
This element represents the portion of accumulated other comprehensive income/loss related to actuarial gains and losses not expected to be amortized to earnings during the next fiscal year.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Provides an entity's explanation that the preparation of financial statements in conformity with generally accepted accounting principles requires the use of management estimates. Estimates used in the determination of carrying amounts of assets or liabilities, or in disclosure of gain or loss contingencies should be disclosed if known information available prior to issuance of the financial statements indicates that both of these criteria are met: (1) It is at least reasonably possible that the estimate of the effect on the financial statements of a condition, situation, or set of circumstances that existed at the date of the financial statements will change in the near term (less than one year from the date of issuance) due to one or more future confirming events, and (2) The effect of the change would be material to the financial statements. The disclosure should indicate the nature of the uncertainty and include an indication that it is at least reasonably possible that a change in the es
timate will occur in the near term. Disclosure of the factors that cause the estimate to be sensitive to change also is encouraged. Entities also may identify those areas that are subject to significant estimates.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
This element represents the adjustment to principal value of long term debt related to the unamortized basis adjustment from swap terminations.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The amount of gain/loss on sale of discontinued operations affecting cash flows during the period.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The change in noncontrolling interest during the period attributable to adjustments to the net asset transfer related to a split-off transaction.
No authoritative reference available.
The amount of damages sought from a third party related to litigation.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The change in noncontrolling interest attributable to the initial public offering of a subsidiary.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Schedule Of Additional Information Related To Pension Plans [Text Block]
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Derivative Instruments Qualifying As Cash Flow Hedges Impact On OCI And Earnings [Text Block]
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Short Term Borrowing And Long Term Debt [Text Block]
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
This item represents the disclosure of summarized financial information for unconsolidated subsidiaries and 50 percent-or-less owned entities accounted for using the equity method of accounting. If investments in common stock of corporate joint ventures or other investments accounted for under the equity method are, in the aggregate, material in relation to the financial position or results of operations of an investor, it may be necessary to present summarized information as to assets of the investee, or group of investments for which combined disclosure is appropriate, either by individual financial statement caption or in groups, as appropriate. Included here is marketing, selling, and administrative expense of the equity method subsidiary.
No authoritative reference available.
Inventory Subject To FDA Approval
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Earnings Per Share Numerator Basic
No authoritative reference available.
The amount of previously capitalized milestone payments included in intangible assets, which are amortized to cost of products sold over the remaining life of the agreement.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The amount of operating expenses reimbursed by the collaboration partner pursuant to the terms of the agreement.
No authoritative reference available.
The equity interest of controlling shareholders in the consolidated entity.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The change in additional paid in capital attributable to an asset transfer adjustment.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The cash inflow associated with the sale and subsequent leaseback of property, plant, and equipment.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Describes an entity's accounting policy for its research and development.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
This element represents all other gain/loss associated with debt repurchases including the portion of the basis adjustment for previously terminated swaps recognized in earnings.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Schedule Of Assumed Healthcare Cost Trend Rates [Text Block]
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Describes an entity's accounting policy for sales rebate and return accruals.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The percentage to be subtracted from the London Interbank Offered Rate (LIBOR) to calculate quarterly interest
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The percentage of certain commercial operational expenses reimbursed to the Company by alliances and collaborations.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Schedule Of Provision For Tax [Text Block]
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
This element represents the number of years used in the historical volatility calculation.
No authoritative reference available.
This item represents the disclosure of summarized financial information for unconsolidated subsidiaries and 50 percent-or-less owned entities accounted for using the equity method of accounting. If investments in common stock of corporate joint ventures or other investments accounted for under the equity method are, in the aggregate, material in relation to the financial position or results of operations of an investor, it may be necessary to present summarized information as to assets of the investee, or group of investments for which combined disclosure is appropriate, either by individual financial statement caption or in groups, as appropriate. Included here is advertising and product promotion expense of the equity method subsidiary.
No authoritative reference available.
Contingent payment to be recognized upon first approval in certain territories.
No authoritative reference available.
The amount of acquisition cost of a business combination allocated to other current and noncurrent liabilities of the acquired entity.
No authoritative reference available.
Earnings from discontinued operations attributable to unvested restricted shares for earnings per share calculation.
No authoritative reference available.
This item represents the disclosure of summarized financial information for unconsolidated subsidiaries and 50 percent-or-less owned entities accounted for using the equity method of accounting. If investments in common stock of corporate joint ventures or other investments accounted for under the equity method are, in the aggregate, material in relation to the financial position or results of operations of an investor, it may be necessary to present summarized information as to assets of the investee, or group of investments for which combined disclosure is appropriate, either by individual financial statement caption or in groups, as appropriate. Included here is other income/expense of the equity method subsidiary.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Schedule Of Percentage Of Total Gross Sales [Text Block]
No authoritative reference available.
This element represents unusual or infrequent items during the period related to product liability charges.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Schedule Of Other Intangible Assets [Text Block]
No authoritative reference available.
The amounts in accumulated other comprehensive income related to gains and losses and prior service cost that are not recognized immediately and are expected to be recognized as components of net periodic benefit cost over the next fiscal year that follows the most recent annual statement of financial position presented.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The notional amount of debt repurchased during the period.
No authoritative reference available.
The aggregate amount of expense recognized in other income/expense due to settlements and curtailments.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Schedule Of Percentage Received in Net Sales
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The percentage of pension plan equity investments that are actively managed.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Schedule of Deferred Income Text Block
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The gain/loss recognized in other income/expense during the period for the net overhedged portion of non-derivative debt designated as a hedge of a net investment.
No authoritative reference available.
Accrued Expenses [Text Block]
No authoritative reference available.
Schedule Of Amortization Of Actuarial Loss And Prior Service Cost
No authoritative reference available.
The notional amount of an interest rate swap agreement terminated during the period.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
This element represents the total unusual or infrequent items during the period.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Receivables reclassified to other long-term assets
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
This element represents unusual or infrequent items during the period related to a tax charge.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
This element represents unusual or infrequent items during the period related to the gain/loss on debt buybacks and interest rate swap terminations.
No authoritative reference available.
The closing price on the transaction date utilized to value parent company shares received in the split-off transaction.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
This element represents the total gain/loss recognized in earnings related to debt extinguishment, including the gain/loss on extinguishment, interest rate swap termination proceeds, and other gain/loss.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The amount of deferred income related to upfront, licensing, and milestone payments received from collaboration partners as of balance sheet date. These payments are recorded as a liability, and are subsequently recognized into other income/expense ratably over the applicable amortization period as income is earned.
No authoritative reference available.
The number of personnel receiving termination benefits for workforce reduction included in restructuring charges.
No authoritative reference available.
The amount of upfront licensing and milestone payments that could be paid if all remaining development, regulatory, or sales-based milestones are met.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
This element represents the payout percentage used in the calculation of outstanding long term performance awards.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The aggregate fair value of financial assets as of the balance sheet date.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Sum of the gross carrying amounts before accumulated amortization as of the balance sheet date of all intangible assets, excluding goodwill.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Income/Loss attributable to discontinued operations attributable to the parent company, net of tax, that is used in the basic earnings per share calculation.
No authoritative reference available.
The term, in years, that the tolling agreement can be extended.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The amount of cash paid during the period as a result of significant litigation.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The percentage of the product selling effort to be reimbursed by the collaboration partner.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Amounts due from alliance or collaborations, due within one year.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Capitalized costs related to production of products for programs in phase III development subject to final US food and drug administration approval included in inventory.
No authoritative reference available.
The percentage of annual net sales of certain products payable as a collaboration fee to third parties in alliances and collaborations.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The maximum contractual term of stock options, in years.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The year of maturity for the interest rate swap.
No authoritative reference available.
Gain Loss On Debt Repurchase
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
This element represents the aggregate pre-tax income/expense recognized during the period related to interest rate swap terminations. This includes the amortization of the basis adjustment from swap terminations which is included in interest expense and the gain on swap terminations recognized in other income/expense.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
he number of shares into which fully or partially vested stock options outstanding including those which are exercisable
No authoritative reference available.
Percentage of subsidiary's combined voting interest in outstanding common stock owned by the parent company after the stock transaction.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Purchase Price Allocation, Other Net Asset Amount
No authoritative reference available.
Schedule Of Changes In Other Intangible Assets [Text Block]
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Schedule Of Weighted Average Assumptions Used To Determine Benefit Obligations [Text Block]
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The amount of upfront licensing and milestone payments that could be received if all remaining development, regulatory, or sales-based milestones are met.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The historical long-term actual annualized returns for United States defined benefit pension plans expressed as a percentage.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Schedule Of Accrued Expenses [Text Block]
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The reduction of net sales in the period representing the allocation of an extension payment to periods expected to benefit from such costs, such as the extension period.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Adjusted Purchase Price Allocation [Text Block]
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Describes an entity's accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets. Additionally, also describes an entity's accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.
No authoritative reference available.
Cash Cash Equivalents And Marketable Securities [Text Block].
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Schedule Of Quarterly Financial Information [Text Block]
No authoritative reference available.
The gains included in earnings resulting from the sale of product lines, businesses, and assets.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The percentage of certain commercial operational expenses reimbursed to the Company by alliances and collaborations.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The aggregate amount of upfront milestone payments paid to a collaboration partner to date.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Schedule Of Income Loss From Continuing Operations Before Tax [Text Block]
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The total fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares, other instruments, or cash in accordance with the terms of the arrangement.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The portion of nonderivative instruments formerly designated as the hedging instruments in hedge transactions of net investments in foreign operations that have been dedesignated.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Amount borrowed under a related party credit facility as of the balance-sheet date.
No authoritative reference available.
This element represents income taxes on net earnings attributable to noncontrolling interest.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Schedule of Stock Option Activity[Text Block]
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The number of years in the tolling and manufacturing agreement.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits, that are expected to be paid within one year.
No authoritative reference available.
Schedule Of Major Tax Jurisdictions [Text Block]
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
This amount reflects the net periodic benefit cost for the period before settlements and curtailments.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Schedule Of Changes In Valuation Allowance [Abstract]
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The minimum percentage payout factor of share based compensation equity awards. The payout factor is the share price on vesting date divided by share price on award date. The share price used in the payout factor is calculated using an average of the closing prices on the grant or vest date, and the nine trading days immediately preceding the grant or vest date.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Initial Public Offering [Text Block]
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The term, in years, of the cycle of long-term performance awards.
No authoritative reference available.
Schedule Of Percentage Net Sales Annually
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Summarized Financial Information Reflected In Consolidated Balance Sheet [Text Block]
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The carrying amount as of the balance sheet date of the termination indemnity obligations recognized for certain statutory termination obligations in Europe. These obligations are recognized on an undiscounted basis assuming employee termination at each measurement date.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The employer's best estimate, as soon as it can be reasonably determined, of the minimum contributions expected to be paid to the plan during the next fiscal year beginning after the date of the latest statement of financial position.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The tax effect as of the balance sheet date of the amount of the estimated future tax deductions arising from pension and postretirement benefits costs, which can only be deducted for tax purposes when actual costs are incurred, and which can only be realized if sufficient tax-basis income is generated in future periods to enable the deduction to be taken.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The maximum number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Schedule of Changes in Defined Benefit and Postretirement Benefit Plan Obligations, Assets, Funded Status and Amount Recognized in the Consolidated Balance Sheets
No authoritative reference available.
The percentage of pension plan equity investments that are comprised of Company stock.
No authoritative reference available.
The term, in years, that share based equity awards vest over.
No authoritative reference available.
Earnings Attributable To Unvested Restricted Shares
No authoritative reference available.
The gross amount of increases or decreases in unrecognized tax benefits resulting from foreign currency translation adjustments.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Tax effect of the reclassification adjustment for accumulated gains and losses from derivative instruments designated and qualifying as the effective portion of cash flow hedges included in accumulated comprehensive income/loss that was realized in net income during the period related to business divestitures.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The year in which the interest rate swap to convert fixed rate debt to floating rate debt was executed.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The percentage of certain development expenses reimbursed to the Company by alliances and collaborations.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The amount by which the fair value of defined benefit plan assets exceeds market-related value. The market-related value is a calculated value of assets used in determining the expected return on defined benefit plan assets.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The percentage of aggregate trade receivables due from customers accounting for more than 10% of total trade receivables.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The total restructuring and other activities that were specified and reduced net earnings from continuing operations during the period, pre-tax.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
This element represents the percentage of the greater of the market-related value of plan assets or projected benefit obligation not amortized from accumulated other comprehensive income into earnings.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The equivalent per share amount to be paid upon conversion of certain convertible debt.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Amount of the period's gross receipts received from the prescription drug subsidy, which is to be used in the roll forward of the fair value of plan assets of an applicable postretirement benefit plan.
No authoritative reference available.
Variable Rate Received
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The amount paid during the period to a collaboration partner, expensed as research and development, for the collaboration partner to opt out of certain further codevelopment.
No authoritative reference available.
The amount of upfront milestone payments paid to a collaboration partner, expensed as research and development.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
This element represents unusual or infrequent items during the period related to an acquisition.
No authoritative reference available.
The gross change during the period in the spot value of non-derivative debt designated as a hedge of a net investment.
No authoritative reference available.
Cash And Cash Equivalents Maintained In Foreign Currencies
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
This element represents the aggregate amount recognized in earnings during the period related to interest rate swaps that qualified as fair value hedges.
No authoritative reference available.
The percentage at which shared based equity awards vest over the applicable vesting period.
No authoritative reference available.
Accumulated change, pretax, in accumulated gains and losses from derivative instruments designated and qualifying as the effective portion of cash flow hedges. Includes an entity's share of an equity investee's increase (decrease) in deferred hedging gains or losses.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The maximum percentage payout factor of share based compensation equity awards. The payout factor is the share price on vesting date divided by share price on award date. The share price used in the payout factor is calculated using an average of the closing prices on the grant or vest date, and the nine trading days immediately preceding the grant or vest date.
No authoritative reference available.
The amount of acquisition cost of a business combination allocated to other current and other noncurrent assets.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The portion of nonderivative instruments formerly designated as the hedging instruments in hedge transactions of net investments in foreign operations that have been dedesignated.
No authoritative reference available.
The proceeds generated from the termination of interest rate swap agreements.
No authoritative reference available.
The amount of financial guarantees provided by the Company in the form of stand-by letters of credit and performance bonds.
No authoritative reference available.
Reflects the interest rate as of the balance sheet date on interest-bearing note receivables.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The loss recognized in earnings related to the sale of ownership interest in certain investments.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The aggregate amount of intangible assets acquired in the period.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Schedule Of Debt repurchased And Notional Amount Of Interest Rate Swap
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The charge recognized in other income/expense during the period related to the imputed discount on certain non-interest bearing loans.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The portion of net income (loss) attributable to the noncontrolling interest (if any) deducted in order to derive the portion attributable to the parent.
No authoritative reference available.
The amount of fixed rate debt converted to variable rate debt through an interest rate swap fair value hedge during the period.
No authoritative reference available.
The percentage of certain third party net sales recognized in net sales as defined in the commercialization agreement.
No authoritative reference available.
Sales Rebates And Return Accruals.
No authoritative reference available.
The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Expense recognized in cost of products sold as a distribution fee pursuant to the collaboration agreement during the period.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The aggregate fair value of financial liabilities as of the balance sheet date.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Payment made to extend the term of the commercialization and manufacturing agreement, which is included in other assets and is amortized as a reduction of net sales through the extension period.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The number of the largest pharmaceutical wholesalers used by the company in the territory.
No authoritative reference available.
The percentage at which options become exercisable on each grant date anniversary.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The cash inflow from proceeds associated with the termination of interest rate swaps.
No authoritative reference available.
Schedule Of Estimated Useful Lives Of The Major Depreciable Assets [Text Block]
No authoritative reference available.
The amount of reductions to trade accounts receivables, including charge-backs related government programs and cash discounts.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Disclosure relates to accounts comprising shareholders' as well as noncontrolling interest equity, including other Comprehensive income. Includes: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated p
referred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions;
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
This element reflects the line of credit facility financial covenant ratio that the consolidated net debt to consolidated capital cannot exceed a certain percentage.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Schedule Of Unrecognized Tax Benefits [Text Block]
No authoritative reference available.
Net of tax effect of the reclassification adjustment for accumulated gains and losses from derivative instruments designated and qualifying as the effective portion of cash flow hedges included in accumulated comprehensive income/loss that was realized in net income during the period related to business divestitures.
No authoritative reference available.
Summarized Financial Information Accounted For Under Equity Method [Text Block]
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The total loss related to the disposal of manufacturing operations, including impairment charges, working capital adjustments, and transaction related fees.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Schedule Of Receivables [Text Block]
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The percentage of revenue generated from a single external customer that accounts for 10 percent or more of an entity's revenues.
No authoritative reference available.
The noncurrent portion of deferred income as of balance sheet date. Deferred income is a liability related to a revenue or other income producing activity for which revenue or other income has not yet been recognized, and is not expected to be recognized in the next twelve months. Deferred income is recorded when consideration from a customer is received before achieving certain criteria that must be met for revenue or other income to be recognized in conformity with GAAP.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The percentage of net sales of certain products in certain territories payable as a distribution fee pursuant to the collaboration agreement to other collaboration partners.
No authoritative reference available.
The employer's best estimate, as soon as it can be reasonably determined, of the maximum contributions expected to be paid to the plan during the next fiscal year beginning after the date of the latest statement of financial position.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Schedule Of Activity For Financial Assets Utilizing Level 3 Fair Value Measurements
No authoritative reference available.
Schedule of Significant Ranges of Outstanding and Exercisable Options [Text block]
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Schedule Of Capital Expenditure And Depreciation Of Property Plant And Equipment Within the Biopharmaceuticals Segment [Text Block]
No authoritative reference available.
Schedules of Interest Rate Swaps Outstanding [Text Block]
No authoritative reference available.
Reflects when the related party credit facility terminates, which may be presented in a variety of ways (year, month and year, day, month and year, quarter).
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Debt Instrument Due Date
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The number of subsidiary's stock owned by parent company after stock transaction.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The amount of debt principal to be converted to a certain number of shares upon conversion of the debt to equity.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
This element represents the change in noncontrolling interest related to the split-off transaction.
No authoritative reference available.
This element represents the total tax related to unusual or infrequent items during the period.
No authoritative reference available.
The amount of cash offered per share through a tender offer related to the acquisition of a business.
No authoritative reference available.
Total current and noncurrent debt and equity financial instruments including: (1) securities held-to-maturity, (2) trading securities, and (3) securities available-for-sale
No authoritative reference available.
The maximum amount of certain operational expenses for the collaboration reimbursement percentage.
No authoritative reference available.
The number of parent company shares received in the split-off transaction and reflected as treasury stock.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The amount of common stock authorized to be repurchased as part of a stock repurchase program.
No authoritative reference available.
Schedule of Stock Compensation Plans and Currently Outstanding and Exercisable Options[Text Block]
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
"Describes an entity's accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally.
No authoritative reference available.
Purchase Price Allocation [Text Block]
No authoritative reference available.
This item represents the disclosure of summarized financial information for unconsolidated subsidiaries and 50 percent-or-less owned entities accounted for using the equity method of accounting. If investments in common stock of corporate joint ventures or other investments accounted for under the equity method are, in the aggregate, material in relation to the financial position or results of operations of an investor, it may be necessary to present summarized information as to assets of the investee, or group of investments for which combined disclosure is appropriate, either by individual financial statement caption or in groups, as appropriate. Included here is research and development expense of the equity method subsidiary.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Interest Rate Swaps Qualified As Fair Value Hedges Impact On Earnings [Text Block]
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Treasury Stock Value Acquired Cost Method Transaction Fees
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The weighted-average remaining lives of the participants utilized to amortize actuarial gains and losses.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Schedule Of Estimated Future Benefit Payments [Text Block]
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The carrying amount of intangible assets transferred as a result of a subsidiary splitoff.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Schedules of Significant Outstanding Foreign Currency Forward Contracts [Text Block]
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The weighted-average grant date fair value of equity instruments other than options that are expected to vest.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Schedule Of Weighted Average Actuarial Assumptions Used To Determine Net Periodic Benefit Cost [Text Block]
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The income tax attributable to certain restructuring and other activities.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The pre-tax portion of income (loss) attributable to the noncontrolling interest (if any) deducted in order to derive the portion attributable to the parent.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Summarized Financial Information Reflected In Consolidated Financial Statements [Text Block]
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The net amount of other income and expense which does not qualify for separate disclosure under materiality guidelines.
No authoritative reference available.
The number of years in which available for sale securities reach maturity.
No authoritative reference available.
This element represents the proceeds received or paid upon termination of the interest rate swap.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Expense recognized related to working capital adjustments and transaction related fees on the loss on sale of manufacturing operations.
No authoritative reference available.
Summarized Financial Information [Text Block]
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The net amount of income recognized in other income/expense related to an acquisition. Includes transaction costs recognized as other expense and income recognized from the remeasurement to fair value of the equity interest in acquiree held at the acquisition date . Transaction costs includes direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.
No authoritative reference available.
Schedule of Input Variables Used In Calculation Of Fair Value Of Market Share Units [Text Block]
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
This element represents unusual or infrequent items during the period related to litigation charges.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The number of lawsuits in which the Company was a defendant.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The number of share based compensation stock options that are "in-the-money" and exercisable as of the balance sheet date.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The amount of debt principal relieved upon conversion to cash prior to maturity.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The aggregate amount of changes not specified otherwise in intangible assets during the period.
No authoritative reference available.
The amount of principal at par of floating rate securities received during the period.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Schedule Of Effect Of One Percentage Point Change In Assumed Health Care Cost Trend Rates [Text Block]
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Schedule Of Inventory [Text Block]
No authoritative reference available.
Schedule Of Components Of Current And Non Current Deferred Income Tax Assets Liabilities [Text Block]
No authoritative reference available.
This element represents unusual or infrequent items during the period related to an impairment of in-process research and development.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The value of parent company shares received in the split-off transaction and reflected as treasury stock.
No authoritative reference available.
The amount of allowances for charge-backs, discounts, and doubtful accounts attributable to discontinued operations.
No authoritative reference available.
The tax reserve included in determining the gain on exchange of the split off transaction.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The cash inflow associated with proceeds from the initial public offering of a subsidiary's common stock.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The amount of cash payable upon conversion of a certain amount of debt principal outstanding prior to maturity
No authoritative reference available.
Schedule of Income Expense Recognized
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The aggregate amount of milestone payments paid to a collaboration partner.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
For leases having an initial or remaining non-cancelable letter-terms in excess of one year, required rental payments due in the aggregate, net of total minimum sublease rental receivables
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Schedule Of Reconciliation Of Effective Tax Rate To The U S Statutory Federal Income Tax Rate [Text Block]
No authoritative reference available.
The notional amount of debt repurchased during the period.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The current portion of deferred income as of balance sheet date. Deferred income is a liability related to a revenue or other income producing activity for which revenue or other income has not yet been recognized, and is expected to be recognized in the next twelve months. Deferred income is recorded when consideration from a customer is received before achieving certain criteria that must be met for revenue or other income to be recognized in conformity with GAAP.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The value of ownership interest in certain investments which are allocated to other current and noncurrent assets as part of the acquisition cost of a business combination.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The aggregate expense included in discontinued operations to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Summarized Financial Information, Balance Sheet [Text Block]
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Impact On OCI And Earnings From Non Derivative Debt Designated Net Investment Hedges Table [Text Block]
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
This element represents unusual or infrequent items during the period related to losses on the sale of investments.
No authoritative reference available.
The amount of damages awarded during the period.
No authoritative reference available.
The percentage of sales within a range of total sales to be recognized pursuant to the collaboration agreement.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Describes the entity's accounting policy for recognizing accruals for product liabilities and third-party recoveries for product liabilities.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The amount of upfront licensing and milestone payments received by the Company that is amortized from deferred income over the useful life of the products into other income.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Payments To Participants
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The amount of acquisition cost of a business combination allocated to short term borrowings assumed from the acquired entity.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Schedule Of Historical Long Term Actual Annualized Returns For US Pension Plans [Text Block]
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Schedule of Stock Option Grants and Exercised [Text Block]
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The amount of collaboration fees recognized in cost of products sold for the period.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Earnings Per Share Numerator Diluted
No authoritative reference available.
The percentage of the consolidated pension plan assets and obligations attributable to a specific defined benefit pension plan.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The amount of debt issued by a related party to satisfy intercompany debt prior to the split-off date.
No authoritative reference available.
This element represents unusual or infrequent items during the period related to out of period tax adjustments.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The amount of development expenses reimbursed by the collaboration partner pursuant to the terms of the agreement that are netted in research and development expense.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The change in additional paid in capital attributable to the initial public offering of a subsidiary.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The percentage of collaboration profits for certain products in certain territories recognized by the Company.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Earnings Per Share Calculation Components [Text Block]
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The tax effect as of the balance sheet date of the amount of the estimated future tax deductions arising from milestone payments and license fees, which can only be realized if sufficient tax-basis income is generated in future periods to enable the deduction to be taken.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The maximum amount of payments for half of the costs of the class notice.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The amount of amortization expense expected to be recognized after the fifth twelve-month period following the balance sheet date.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The amount of receivables sold on a nonrecourse basis during the year.
No authoritative reference available.
This element reflects the term, in years, of the credit facility.
No authoritative reference available.
The percentage of development costs for studies in certain territories to be funded by the Company.
No authoritative reference available.
The amount of alliance partner receivables that is netted with deferred income until recognition of income.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Accumulated change in accumulated gains and losses from nonderivative instruments designated as hedge of a net investment reflected in accumulated other comprehensive income/loss.
Includes foreign currency transactions designated as hedges of net investment in a foreign entity and intercompany foreign currency transactions that are of a long-term nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting enterprise's financial statements.
No authoritative reference available.
Schedule Of Selected Geographic Area Information [Text Block]
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Purchase Price Allocation, Research And Devlopment Amount
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Prime money market funds, net asset value, per share amount.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
This element represents the period in days in which cash flow hedge accounting is discontinued when the forecasted transaction is no longer probable of occurring on the originally forecasted date or thereafter.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The number of plaintiffs in certain lawsuits filed against the Company.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Amount of previously reported deferred income related to alliances and collaborations that was recognized as income during the period.
No authoritative reference available.
This element represents the total impact on earnings related to unusual or infrequent items during the period.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Carrying value as of balance sheet date of accrued rebates and returns, including government program rebates and customer product sales returns.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Additional contingent charges related to an obligation to fund a portion of restructuring costs of a third party subject to the terms of the asset sales agreement.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The percentage of certain third party net sales and the related cost of products sold and expenses recognized in earnings as defined in the commercialization agreement.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Amount of previously reported deferred income that was recognized as other income during the period.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The number of shares of previously held subsidiary common stock exchanged in the split-off transaction.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
This item represents the disclosure of summarized financial information for unconsolidated subsidiaries and 50 percent-or-less owned entities accounted for using the equity method of accounting. If investments in common stock of corporate joint ventures or other investments accounted for under the equity method are, in the aggregate, material in relation to the financial position or results of operations of an investor, it may be necessary to present summarized information as to assets of the investee, or group of investments for which combined disclosure is appropriate, either by individual financial statement caption or in groups, as appropriate. This item represents the aggregate amount of current receivables/payables to the joint venture partners, net of cash distributions and intercompany balances.
No authoritative reference available.
The amount of deferred income not otherwise specified as of the balance sheet date.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
As of the balance sheet date, the number of nonvested restricted stock shares/units expected to vest.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Fair Value Of Outstanding Derivatives [Text Block]
No authoritative reference available.
The ownership interest percentage in certain investments which are allocated to other current and noncurrent assets as part of the acquisition cost of a business combination.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
Deferred income is a liability related to a revenue or other income producing activity for which revenue or other income has not yet been recognized. Deferred income is recorded when consideration from a customer is received before achieving certain criteria that must be met for revenue or other income to be recognized in conformity with GAAP.
No authoritative reference available.
Out of period tax adjustment net deferred tax assets.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
The notional amount of derivatives in natural gas contracts, measured in decatherms.
No authoritative reference available.
Schedule of Other Income Expenses
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
This element represents unusual or infrequent items during the period related to not-for-profit foundation funding charges.
No authoritative reference available.
No authoritative reference available.
No authoritative reference available.
